MicroPort’s Wright Bid Creates New Ortho Player

Wright Medical’s decision to sell its hip and knee business wasn’t entirely unexpected. The buyer, the Chinese company MicroPort, may have surprised some, but changes in orthopedics and the device industry as a whole could make such deals more common.

Wright Medical Group NV’s decision to sell its hip and knee joint business shouldn’t really have surprised anyone. [See Deal] CEO Robert Palmisano – in the eyes of one Wall Street analyst – is a “money maker” who has generated significant returns for investors by guiding businesses like eye company IntraLase Corp. and peripheral vascular player ev3 Inc. into the arms of larger strategic acquirers, Abbott Laboratories Inc.’s Abbott Medical Optics Inc. (then called Advanced Medical Optics) and Covidien Ltd., respectively. [See Deal][See Deal] Wright watchers say Palmisano had set a similar course for Wright when he joined as CEO in 2011. Early on, he divided the company into two distinct businesses, one focusing on the high-growth extremities sector and the other centered on the low-growth large joint sector. Given the divergent fates of the two sectors, it wasn’t difficult to guess which business was on the way out.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Asia

Indian Medtechs Call US Tariffs A Challenge To Growth And Seek Reciprocal Regulatory Access

 
• By 

India’s medical technology industry is raising the alarm over steep new US tariffs on imported medical devices. It argues for structural change to address “unequal regulatory access” and non-tariff barriers.

US FDA Teleconferences In As IMDRF Gathers In Tokyo

 
• By 

The International Medical Device Regulators Forum discussed AI regulation, the development of a reliance playbook, and post-market regulation at the group's annual meeting in Tokyo last week. While the US FDA was not on-site, the agency was able to participate virtually.

Amplitude Acquisition Marks Global Medtech Entry With High Potential In India For Zydus

 
• By 

Zydus Lifesciences plans to expand global markets for patented products of French orthopedic tech company Amplitude Surgicals which it is acquiring from PE firm PAI Partners and others. Could the European business also serve as a buffer to upheaval in the US amid talks of tariffs?

China Strikes Back After Trump Ups Tariffs; Administration Further Delays Tariffs On Canada And Mexico

 

In response to the Trump administration increasing its tariffs on imports from China, Beijing announced a ban on gene sequencers from US biotech firm Illumina, signaling a full-blown trade war could be in the making. Trump also pushed the deadline for implementing tariffs on Canada and Mexico back by another month.

More from Geography

Guidance Feedback Highlights Outstanding Questions In AI Development

 
• By 

Many of the hundred-plus commenters to the FDA's draft guidance on AI in medical product regulation said the document was a good start but needed additional clarity and more concrete examples. Stakeholders recommended the inclusion of case studies, metrics, and clearer guidelines to enhance the utility of the guidance, which is seen as a vital step for AI integration in healthcare.

Keeping Germany’s Medtech Industry Apprised, Advised and Incentivized in Turbulent Times

 
• By 

A change of government, hospital reform and a drive towards healthcare digitization are keeping German medtech manufacturers on their toes. Making the MDR more user-friendly and winning support for a medtech strategy are arguably bigger priorities. US export tariffs have also pushed their way onto the agenda. BVMed chief executive Marc-Pierre Möll puts it all into context.

Indian Medtechs Call US Tariffs A Challenge To Growth And Seek Reciprocal Regulatory Access

 
• By 

India’s medical technology industry is raising the alarm over steep new US tariffs on imported medical devices. It argues for structural change to address “unequal regulatory access” and non-tariff barriers.